CN115141150A - 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative and preparation method and application thereof - Google Patents
2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN115141150A CN115141150A CN202210876172.XA CN202210876172A CN115141150A CN 115141150 A CN115141150 A CN 115141150A CN 202210876172 A CN202210876172 A CN 202210876172A CN 115141150 A CN115141150 A CN 115141150A
- Authority
- CN
- China
- Prior art keywords
- amino
- hydroxylamine
- trisubstituted pyrimidine
- inhibitor
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 23
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 23
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 17
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- -1 2,4,5-trisubstituted pyrimidine hydroxylamine Chemical class 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000012065 filter cake Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 5
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 claims description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- CZSAQVUTTJIFQH-UHFFFAOYSA-N hydroxylamine pyrimidine Chemical class ON.C1=CN=CN=C1 CZSAQVUTTJIFQH-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 3
- 238000004809 thin layer chromatography Methods 0.000 claims 3
- 229940125436 dual inhibitor Drugs 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 150000002894 organic compounds Chemical class 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 2
- HNBDRPTVWVGKBR-UHFFFAOYSA-N methyl pentanoate Chemical compound CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- XNCNNDVCAUWAIT-UHFFFAOYSA-N Methyl heptanoate Chemical compound CCCCCCC(=O)OC XNCNNDVCAUWAIT-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000005463 Tandutinib Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- PHRZTXWNFAEVIA-UHFFFAOYSA-N hydroxylamine;potassium Chemical compound [K].ON PHRZTXWNFAEVIA-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- 229950009893 tandutinib Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
The invention belongs to the field of organic compound synthesis and medical application, and relates to a2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative, and a preparation method and application thereof. The 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative provided by the invention has the structure shown as the general formula IWherein n is 1,2,3,4,5,6,7; r 1 One selected from hydrogen, halogen, trifluoromethyl and methyl. The 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative has certain HDAC and/or FLT3 dual-inhibition activity, and can be applied to preparation of anti-cancer drugs.
Description
Technical Field
The invention belongs to the field of organic compound synthesis and medical application, and relates to a2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative, a preparation method and application thereof, in particular to a (2- ((4-phenoxyphenyl) amino) pyrimidine-4-yl) amino acid derivative, a preparation method and application thereof.
Background
In the body, the enzyme responsible for regulating histone deacetylation is Histone Deacetylase (HDAC). Under normal conditions, this enzyme is in a state of dynamic equilibrium, maintaining normal expression and transcription of genes, and HDAC is abnormally expressed in various malignancies, and thus, HDAC is currently considered to be an effective target for the treatment of hematologic malignancies (Blood 2016 (18): 2168-2170 and Blood 201122 (21): 5142. FMS-like tyrosine kinase 3 (FMS-like receptor tyrosine kinase, FLT 3) is a transmembrane protein, is uniformly expressed on leukemia primitive cells of Acute Myelogenous Leukemia (AML), acts on hematopoietic stem/histiocyte regions (see Blood 2018 132 ((Supplement _ 1): 903 and Blood 2020 (136 (21): 2442-2456), and is an important target for treating hematological malignancies and autoimmune diseases). Preclinical and clinical studies show that double inhibition of HDAC and FLT3 has a coordinating effect (see Blood 2019 (Supplement _ 1): 1268), so that a novel HDAC/FLT3 double-target drug with a novel structure and drug-forming property is designed and synthesized, and has a very important significance for treating hematological malignancies.
Disclosure of Invention
The invention aims to provide 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivatives, a preparation method and application thereof, the compounds have HDAC/FLT3 dual inhibition activity and 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivatives with anti-tumor effect, and the compounds have excellent biological activity.
In order to achieve the purpose, the technical scheme of the disclosure is as follows:
in a first aspect of the invention, the invention provides a2,4,5-trisubstituted pyrimidine hydroxylamine derivative or a pharmaceutically acceptable salt thereof, having a structure represented by formula I:
wherein n is 1,2,3,4,5,6,7; r is 1 One selected from hydrogen, halogen, trifluoromethyl and methyl.
Preferably, n is 2,3,4,5,6; r is 1 Selected from fluorine.
3- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxypropionamide (A14) (I-1)
4- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxybutyramide (A18) (I-2)
5- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxypentanamide (A29) (I-3)
6- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxyhexanamide (A22) (I-4)
7- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxyheptanamide (A33) (I-5)
The corresponding reference numbers are shown in parentheses after the names of the above 5 compounds, and for the convenience of description and the simplicity of expression, the reference numbers in the parentheses will be directly used in the following description of the present specification.
The compounds of the present invention may be present in free form or further in the form of salts in order to improve water solubility and increase bioavailability.
The term "pharmaceutically acceptable salt" as used herein refers to conventional non-toxic salts, and includes salts formed from the basic amino groups of the compounds of the present application. These salts are well known to those skilled in the art and the skilled artisan can prepare any pharmaceutically acceptable salt provided by the knowledge in the art. In addition, the skilled artisan may choose one salt and leave out another salt depending on solubility, stability, ease of formulation, etc. The determination and optimization of these salts is within the experience of the skilled artisan.
In a second aspect of the invention, there is also provided a process for the preparation of the 2,4,5-trisubstituted pyrimidine hydroxyamide derivative described above comprising carrying out the reaction of the following reaction scheme:
the method comprises the following specific steps:
(1) Raw material 1 and amino acid methyl ester are condensed to obtain intermediate 2.
(2) Condensing the intermediate 2 and 4-phenoxyaniline under the condition of trifluoroacetic acid to obtain an intermediate 3.
(3) The intermediate 3 reacts with hydroxylamine potassium solution to obtain 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative I.
The preparation methods of the intermediate 3 and 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivatives I are concretely as follows.
The preparation method of the intermediate 3 comprises the following steps:
(i) Dissolving the compound 1 and the amino acid methyl ester in isopropanol, adding DIPEA, and reacting at 85 ℃ for 4 hours. TLC detection, complete reaction, cooling to room temperature, precipitation of a large amount of solid, filtration, and recrystallization of a filter cake with ethyl acetate to obtain an intermediate 2.
(ii) Dissolving the intermediate 2 in n-butanol, adding 4-phenoxyaniline, dropwise adding trifluoroacetic acid into the solution, and reacting for 12h at 110 ℃. TLC detection, complete reaction, cooling to room temperature, reduced pressure evaporation to remove solvent, silica gel column chromatography to obtain intermediate 3.
The preparation method of the 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative I comprises the following steps:
preparation of NH from potassium hydroxide, hydroxylamine hydrochloride and anhydrous methanol 2 OK solution. Dissolving intermediate 3 in NH 2 In OK solution, react for 2h at room temperature. TLC detection, complete reaction, decompression evaporation to remove solvent, water addition, pH value adjustment to 6-7 with dilute hydrochloric acid, solid precipitation, filtration, and recrystallization of filter cake with methanol or ethyl acetate to obtain 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative I.
In a third aspect of the invention, the invention also provides a composition comprising the 2,4,5-trisubstituted pyrimidine hydroxylamine derivative or a pharmaceutically acceptable salt thereof as described above.
The pharmaceutical composition provided by the invention can be applied in any mode selected from the following modes: oral, aerosol inhalation, rectal, nasal, vaginal, topical, parenteral such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal or intracranial injection or infusion, or by means of an explanted reservoir, with oral, intramuscular, intraperitoneal or intravenous administration being preferred.
In the fourth aspect of the invention, the invention also provides a pharmaceutical preparation, which comprises the 2,4,5-trisubstituted pyrimidine hydroxylamine derivative or its pharmaceutically acceptable salt or a composition containing the 2,4,5-trisubstituted pyrimidine hydroxylamine derivative or its pharmaceutically acceptable salt and pharmaceutically acceptable auxiliary materials and/or carriers.
The 2,4,5-trisubstituted pyrimidine hydroxylamine derivatives of the present invention or pharmaceutical compositions containing them may be administered in unit dosage form. The administration dosage form can be liquid dosage form or solid dosage form. The liquid dosage form can be true solution, colloid, microparticle, emulsion, or mixed suspension. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, suppository, lyophilized powder for injection, clathrate, landfill, patch, liniment, etc.
The pharmaceutical combination or pharmaceutical preparation of the present invention may further comprise a conventional carrier, wherein the pharmaceutically acceptable carrier includes but is not limited to: ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycerol, sorbates, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, beeswax, lanolin and the like. The carrier may be present in the pharmaceutical composition in an amount of 1% to 98% by weight, typically about 80% by weight. For convenience, the local anesthetic, preservative, buffer, etc. may be dissolved directly in the vehicle.
Oral tablets and capsules may contain excipients such as binding agents, for example syrup, acacia, sorbitol, tragacanth, or polyvinylpyrrolidone, fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, glycine, lubricants such as magnesium stearate, talc, polyethylene glycol, silica, disintegrants such as potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated by methods known in the art of pharmacy.
The oral liquid can be made into water and oil suspension, solution, emulsion, syrup, or dried product, and supplemented with water or other suitable medium before use. Such liquid preparations may contain conventional additives such as suspending agents, sorbitol, cellulose methyl ether, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gelatin, hydrogenated edible fats and oils, emulsifying agents such as lecithin, sorbitan monooleate, gum arabic; or a non-aqueous carrier (which may comprise an edible oil), such as almond oil, an oil such as glycerol, ethylene glycol, or ethanol; preservatives, e.g. methyl or propyl p-hydroxybenzoates, sorbic acid. Flavoring or coloring agents may be added if desired.
Suppositories may contain conventional suppository bases such as cocoa butter or other glycerides.
For parenteral administration, liquid dosage forms are generally prepared from the compound and a sterile carrier. The carrier is preferably water. The compound can be dissolved in the carrier or made into suspension solution according to the different carrier and drug concentration, when making injection solution, the compound is dissolved in water, filtered and sterilized, and then filled into sealed bottle or ampoule.
It will be appreciated that the optimum dosage and spacing of administration of 2,4,5-trisubstituted pyrimidine hydroxylamine derivatives provided by the present invention is determined by the nature of the compound and the conditions of the outer 2,4,5-trisubstituted pyrimidine hydroxylamine derivative such as the form, route and site of administration and the particular mammal being treated, and that such optimum dosage may be determined by conventional techniques. It must also be recognized that the optimal course of treatment, i.e., the daily dosage of 2,4,5-trisubstituted pyrimidine hydroxyamide derivative over a nominal period of time, can be determined by methods known in the art.
In a fifth aspect of the invention, the invention also provides an application of the 2,4,5-tri-substituted pyrimidine hydroxylamine derivative or a pharmaceutically acceptable salt thereof or a composition containing the compound or the pharmaceutically acceptable salt thereof in preparing FLT3 and/or HDAC inhibitor drugs.
The invention also provides the application of the 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative or the pharmaceutically acceptable salt thereof or the composition containing the compound or the pharmaceutically acceptable salt thereof in preparing a medicament for treating tumors.
The following experimental examples are only for illustrating the technical effects of the present invention, but the experimental examples are not intended to limit the present invention.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Example 1: preparation of intermediate 2
The raw materials 2,4-dichloro-5-substituent-pyrimidine (12mmol, 1.2eq), amino acid methyl ester (10mmol, 1.0eq) and DIPEA (10mmol, 1.0eq) were dissolved in 20mL of isopropanol and reacted at 85 ℃ for 4 hours. After the reaction is finished, the reaction liquid is cooled to room temperature, a large amount of solid is separated out, the solid is filtered, and a filter cake is recrystallized by ethyl acetate to obtain an intermediate 2.
Example 2: preparation of intermediate 3
The intermediate 2 (1mmol, 1eq) was dissolved in 30mL of n-butanol, 4-phenoxyaniline (1.1mmol, 1.1eq) was added, 3 drops of trifluoroacetic acid were added dropwise to the solution, and the reaction was heated at 110 ℃ for 12 hours. After the reaction, the reaction mixture was cooled to room temperature, the solvent was distilled off under reduced pressure, and silica gel column chromatography (dichloromethane/methanol = 100.
3-1:3- (5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) propionic acid methyl ester
1 H NMR(400MHz,DMSO-d 6 )δ9.10(s,1H),7.87(d,J=3.7Hz,1H),7.79–7.74(m,2H),7.46(t,J=5.4Hz,1H),7.37–7.32(m,2H),7.08(t,J=7.4Hz,1H),6.95–6.90(m,4H),3.57(q,J=6.9Hz,2H),3.40(s,3H),2.31(t,J=7.2Hz,2H). 13 C NMR(101MHz,DMSO-d 6 )δ167.79,158.52,156.27(d,J=2.5Hz),152.45(d,J=12.3Hz),149.76,141.36(d,J=243Hz),139.00(d,J=19.2Hz),138.09,130.31,122.87,120.18,120.06,117.66,37.13,32.45.MS(ESI)m/z calcd for C 20 H 20 FN 4 O 3 [M+H] + 383.15,found 383.11.
3-2:4- (5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) butyric acid methyl ester
1 H NMR(400MHz,DMSO-d 6 )δ9.04(s,1H),7.87(d,J=3.7Hz,1H),7.74(d,J=9.0Hz,2H),7.52(t,J=5.3Hz,1H),7.38–7.30(m,2H),7.07(t,J=7.4Hz,1H),7.00–6.89(m,4H),3.42(s,3H),3.36-3.32(m,2H),2.02(t,J=7.4Hz,2H),1.88–1.75(m,2H). 13 C NMR(101MHz,DMSO-d 6 )δ169.25,158.58,156.30(d,J=2.5Hz),152.58(d,J=12.4Hz),149.64,141.36(d,J=242Hz),138.88(d,J=18.7Hz),138.17,130.34,122.82,120.27,119.99,117.56,30.42,25.39.MS(ESI)m/z calcd for C 21 H 22 FN 4 O 3 [M+H] + 397.16,found 397.14.
3-3:5- (5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) pentanoic acid methyl ester
1 H NMR(400MHz,DMSO-d 6 )δ9.08(s,1H),7.84(d,J=3.7Hz,1H),7.74(d,J=9.0Hz,2H),7.45(t,J=5.4Hz,1H),7.39–7.30(m,2H),7.06(t,J=7.4Hz,1H),6.99–6.88(m,4H),3.43(s,3H),2.06–1.92(m,2H),1.63–1.47(m,4H). 13 C NMR(101MHz,DMSO-d 6 )δ169.42,158.51,156.30(d,J=2.6Hz),152.57(d,J=12.4Hz),149.71,141.38(d,J=243Hz),138.78(d,J=18.3Hz),138.17,130.34,122.87,120.14,120.03,117.63,32.54,28.99,23.25.MS(ESI)m/z calcd for C 22 H 24 FN 4 O 3 [M+H] + 411.18,found 411.15.
3-4:6- (5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) hexanoic acid methyl ester
1 H NMR(400MHz,DMSO-d 6 )δ9.05(s,1H),7.84(d,J=3.7Hz,1H),7.79–7.71(m,2H),7.46(t,J=5.5Hz,1H),7.38–7.31(m,2H),7.06(t,J=7.4Hz,1H),6.96-6.92(m,4H),3.40(s,3H),1.94(t,J=7.3Hz,2H),1.62–1.46(m,4H),1.32-1.25(m,2H). 13 C NMR(101MHz,DMSO-d 6 )δ169.43,158.52,156.32(d,J=2.5Hz),152.60(d,J=12.4Hz),149.77,141.38(d,J=243Hz),138.73(d,J=19.3Hz),138.15,130.31,122.89,120.07,120.04,117.69,40.32,32.69,29.03,26.59,25.42.MS(ESI)m/z calcd for C 23 H 26 FN 4 O 3 [M+H] + 425.19,found 425.16.
3-5:7- (5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) heptanoic acid methyl ester
1 H NMR(400MHz,DMSO-d 6 )δ9.06(s,1H),7.85(d,J=3.7Hz,1H),7.77(d,J=9.0Hz,2H),7.43(t,J=5.3Hz,1H),7.37–7.29(m,2H),7.07(t,J=7.4Hz,1H),6.98–6.88(m,4H),3.40(s,3H),1.91(t,J=7.3Hz,2H),1.60-1.53(m,2H),1.51–1.42(m,2H),1.35–1.20(m,4H). 13 C NMR(101MHz,DMSO-d 6 )δ169.48,158.49,156.33,152.58(d,J=12.3Hz),149.81,142.62,140.17,138.75(d,J=19.3Hz),138.13,130.31,122.92,120.01(d,J=3.1Hz),117.73,32.67,29.18,28.86,26.74,25.62.MS(ESI)m/z calcd for C 24 H 28 FN 4 O 3 [M+H] + 439.21,found 439.23.
Example 3: preparation of target compound 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative I
KOH (2.85g, 50.9 mmol) and NH were added 2 OH. HCI (2.38g, 34.3mmol) was dissolved in 7mL and 12mL of anhydrous methanol, respectively, to obtain solution A and solution B. Dropwise adding the solution A into the solution B under the ice bath condition, separating out white solid, continuing to react for 1 hour, filtering the precipitate to obtain NH 2 OK solution. Will be intermediateBody 3 (0.50 mmol) was dissolved in 10mL NH 2 In OK solution, stir at room temperature for 2h. After the reaction is finished, the solvent is evaporated under reduced pressure, 20mL of water is added, the pH value is adjusted to 6-7 by 1MHCl, solid is separated out, the filtration is carried out, and a filter cake is recrystallized by methanol/ethyl acetate to obtain the hydroxylamine acyl target compound I.
I-1:3- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxypropanamide
1 H NMR(400MHz,DMSO-d 6 )δ10.45(s,1H),9.12(s,1H),8.78(s,1H),7.86(d,J=3.7Hz,1H),7.79–7.74(m,2H),7.45(t,J=5.4Hz,1H),7.37–7.32(m,2H),7.06(t,J=7.4Hz,1H),6.97–6.91(m,4H),3.59(q,J=6.9Hz,2H),2.33(t,J=7.2Hz,2H). 13 C NMR(101MHz,DMSO-d 6 )δ167.81,158.54,156.29(d,J=2.5Hz),152.45(d,J=12.3Hz),149.76,141.38(d,J=243Hz),139.01(d,J=19.2Hz),138.09,130.31,122.87,120.18,120.06,117.66,37.11,32.47.HRMS(ESI)m/z calcd for C 19 H 19 FN 5 O 3 [M+H] + 384.1472,found 384.1461.
I-2:4- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxybutyramide
1 H NMR(400MHz,DMSO-d 6 )δ10.41(s,1H),9.07(s,1H),8.73(s,1H),7.85(d,J=3.7Hz,1H),7.75(d,J=9.0Hz,2H),7.50(t,J=5.3Hz,1H),7.38–7.30(m,2H),7.06(t,J=7.4Hz,1H),7.00–6.89(m,4H),3.36-3.32(m,2H),2.04(t,J=7.4Hz,2H),1.88–1.75(m,2H). 13 C NMR(101MHz,DMSO-d 6 )δ169.26,158.59,156.30(d,J=2.5Hz),152.58(d,J=12.4Hz),149.64,141.36(d,J=242Hz),138.88(d,J=18.7Hz),138.17,130.31,122.82,120.27,119.98,117.56,30.41,25.39.HRMS(ESI)m/z calcd for C 20 H 21 FN 5 O 3 [M+H] + 398.1628,found 398.1617.
I-3:5- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxypentanamide
1 H NMR(400MHz,DMSO-d 6 )δ10.35(s,1H),9.06(s,1H),8.69(s,1H),7.84(d,J=3.7Hz,1H),7.74(d,J=9.0Hz,2H),7.48(t,J=5.4Hz,1H),7.39–7.30(m,2H),7.06(t,J=7.4Hz,1H),6.99–6.88(m,4H),2.06–1.92(m,2H),1.63–1.47(m,4H). 13 C NMR(101MHz,DMSO-d 6 )δ169.40,158.54,156.30(d,J=2.6Hz),152.57(d,J=12.4Hz),149.71,141.38(d,J=243Hz),138.78(d,J=18.3Hz),138.15,130.31,122.86,120.14,120.03,117.63,32.54,28.99,23.25.HRMS(ESI)m/z calcd for C 21 H 23 FN 5 O 3 [M+H] + 412.1785,found 412.1775.
I-4:6- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxyhexanamide
1 H NMR(400MHz,DMSO-d 6 )δ10.34(s,1H),9.06(s,1H),8.68(s,1H),7.84(d,J=3.7Hz,1H),7.79–7.71(m,2H),7.46(t,J=5.5Hz,1H),7.38–7.31(m,2H),7.06(t,J=7.4Hz,1H),6.96-6.92(m,4H),1.94(t,J=7.3Hz,2H),1.62–1.46(m,4H),1.32-1.25(m,2H). 13 C NMR(101MHz,DMSO-d 6 )δ169.43,158.52,156.32(d,J=2.5Hz),152.60(d,J=12.4Hz),149.77,141.38(d,J=243Hz),138.73(d,J=19.3Hz),138.15,130.31,122.89,120.07,120.04,117.69,40.32,32.69,29.03,26.59,25.42.HRMS(ESI)m/z calcd for C 22 H 25 FN 5 O 3 [M+H] + 426.1941,found 426.1931.
I-5:7- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxyheptanamide
1 H NMR(400MHz,DMSO-d 6 )δ10.33(s,1H),9.06(s,1H),8.68(s,1H),7.83(d,J=3.7Hz,1H),7.75(d,J=9.0Hz,2H),7.45(t,J=5.3Hz,1H),7.37–7.29(m,2H),7.06(t,J=7.4Hz,1H),6.98–6.88(m,4H),1.92(t,J=7.3Hz,2H),1.60-1.53(m,2H),1.51–1.42(m,2H),1.35–1.20(m,4H). 13 C NMR(101MHz,DMSO-d 6 )δ169.46,158.48,156.31,152.58(d,J=12.3Hz),149.80,142.60,140.16,138.75(d,J=19.3Hz),138.13,130.31,122.92,120.01(d,J=3.1Hz),117.73,32.68,29.18,28.87,26.73,25.61.HRMS(ESI)m/z calcd for C 23 H 27 FN 5 O 3 [M+H] + 440.2098,found 440.2088.
Experimental example: 2,4,5-trisubstituted pyrimidine hydroxylamine derivative is used for testing FLT3 and HDAC (histone deacetylase) inhibitory activity and anti-proliferative activity of tumor cells
1) Experiment on FLT3 inhibitory activity:
experimental materials and instruments: the FLT3 kinase inhibitory activity assay was performed with the assistance of eurofinshoma, uk.
The experimental method comprises the following steps: the compounds of the invention were formulated using DMSO in water to give working solutions at 50-fold final assay concentrations. Compound working solution was first added as a first component to the test wells, followed by kinase buffer diluted FLT3 kinase solution. The addition of Mg/ATP initiates the kinase reaction. Subsequently, the reaction was incubated at room temperature for 40 minutes, and a 0.5% phosphoric acid solution was added to terminate the reaction. 10 μ L of the reaction was spotted onto a pad of P30 filter paper, washed 4 times with 0.425% phosphoric acid for 4 minutes each, then washed once with methanol, followed by drying and scintillation counting.
The test was set up with a compound test group (C), a positive control group (P) and a blank control group (B). The positive control group contained no test compound, DMSO was used instead (final concentration 2%), and the other components were identical to the test group (residual kinase activity 100%); staurosporine (staurosporine) was used in place of test compound in the blank control group to eliminate kinase activity and establish a baseline (residual kinase activity 0%).
Half maximal Inhibitory Concentration (IC) was calculated by fitting a curve using Gragphadprism6.0 software with the logarithm of concentration as the abscissa and the inhibition ratio as the center 50 ) The value is obtained. The test results of the target compound on the BTK and FLT3 kinase inhibition activity are shown in the table 1.
TABLE 1 inhibitory Activity of the Compounds of interest on FLT3 at a concentration of 1. Mu.M
IC 50 : half maximal inhibitory concentration
A:IC 50 <1μM;B:1μM<IC 50 <10μM;C:10μM<IC 50
Table 1 experimental data show that most compounds show FLT3 inhibitory activity comparable to that of the positive control drug Tandutinib, especially the IC of compounds I-3, II-1, II-3 and II-5 on FLT3 50 The value is less than 1 mu M, and is obviously superior to the positive control drug Tandatinib.
2) Assay of the inhibitory Activity of Compounds on HDAC:
experimental materials and methods: boc-Lys (acetyl) -AMC (HeLa cell nuclear extraction fluorogenic substrate) was purchased from Bachem AG, switzerland, tris-HCl, trypsin and EDTA were purchased from Sigma-Aldrich, TSA was purchased from Allantin scientific and Biochemical Co., ltd., glycerol, naCl, 96-well flat-bottom fluorescent plate was purchased from Hongfei reagent.
Buffer solution: 15mM Tris-HCl (pH 8.0), 250mM NaCl, 250. Mu.M EDTA,10% glycerol
HDAC enzyme solution: diluting with Buffer according to the test requirement.
Fluorogenic substrate solution: the substrate was dissolved in DMSO to prepare a 30mM stock solution, which was stored at-20 ℃ and diluted to 300. Mu.M with HDAC Buffer at the time of use.
Stopping liquid: 10mg/mL Trypsin,50mM Tris-HCl (pH 8.0), 100mM NaCl, 2. Mu.M TSA.
An enzyme-labeling instrument: the Varioskan Flash spectrographic scanning multifunctional reader.
The experimental steps are as follows:
100% control group: mixing 10 μ L of HDACs enzyme solution with 50 μ L of HDAC Buffer, incubating at 37 deg.C for 5min, adding 40 μ L of substrate solution, further incubating at 37 deg.C for 30min, adding 100 μ L of stop solution, further incubating at 37 deg.C for 20min, and measuring the fluorescence intensity of reaction solution at 390nm/460nm with a microplate reader to obtain 100% group fluorescence.
Blank control group: mixing 40 μ L of the substrate solution with 60 μ L of HDAC Buffer, incubating at 37 deg.C for 30min, adding 100 μ L of stop solution, further incubating at 37 deg.C for 20min, and measuring the fluorescence intensity of the reaction solution at 390nm/460nm with microplate reader, wherein the value is the fluorescence intensity of the blank group.
Experimental groups: mixing 10 mu L of HDACs enzyme solution with 50 mu L of the compound of the invention to be detected diluted by HDAC Buffer, incubating for 5min at 37 ℃, adding 40 mu L of substrate solution, continuing to incubate for 30min at 37 ℃, adding 100 mu L of stop solution, continuing to incubate for 20min at 37 ℃, and measuring the fluorescence intensity of the reaction solution at 390nm/460nm by using an enzyme-labeling instrument, wherein the value is the fluorescence of the compound to be detected at the concentration.
Calculating the inhibition rate under different concentrations according to a formula, performing S-curve fitting by using origin software, and calculating the IC of the compound to be detected 50 Values, as shown in table 2.
TABLE 2 HDAC inhibitory Activity of target Compounds
A:IC 50 <1μM;B:1μM<IC 50 <10μM;C:10μM<IC 50
The experimental data in Table 2 show that the compound I shows better inhibition effect on HDAC, and especially the inhibition activity of the compounds I-3, I-4 and I-5 on HDAC1 and HDAC6 is equivalent to or even better than that of the positive control drug SAHA. Notably, compounds I-3, I-4, I-5 all showed potent inhibition of HDAC and FLT 3.
3) Growth inhibitory activity of compounds on tumor cells experiment:
experimental materials and instruments: jeko-1 cell strain, RPMI-1640 culture medium, fetal bovine serum, PBS buffer solution, penicillin sodium (10000 units/mL) -streptomycin sulfate (10 mg/mL), a CCK-8 kit, an inverted optical microscope, a cell culture box, an ultra-clean workbench, a desktop centrifuge, an enzyme labeling instrument and an ultra-low temperature refrigerator.
The experimental method comprises the following steps:
inoculating the tumor cells in logarithmic growth phase in 96-well culture plate with the number of cells being 1 × 10 4 Adding cell culture solutions of the compounds to be detected with different concentrations into each well, simultaneously establishing a positive control group and a DMSO blank control group, and adjusting the DMSO concentration to be less than or equal to 1 per thousand. Setting 3 multiple wells per concentration, adding completely, placing at 37 deg.C, 5% 2 And (5) incubating in an incubator for 72h. Subsequently 20. Mu.L of CCK-8 solution per well was added and the plates were placed at 37 ℃ 5% CO 2 Continuously incubating for 1-4h in a constant temperature incubator, usingMeasuring absorbance value of the sample at 450nm wavelength by a microplate reader, normalizing the obtained value with a negative DMSO control group, and calculating IC by Prism6.0 software 50 The value is obtained.
TABLE 3 inhibition of Jeko-1 cell growth by compounds of interest
A:IC 50 <2μM;B:2μM<IC 50 <20μM;C:20μM<IC 50
Table 3 experimental data show that most of the compounds have significant antiproliferative activity on Jeko-1 cells, IC of compounds I-1, I-2 and I-3 50 The values were comparable to or even lower than the positive control SAHA.
The above description is only a preferred embodiment of the present disclosure and is not intended to limit the present disclosure, and various modifications and changes may be made to the present disclosure by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present disclosure should be included in the protection scope of the present disclosure.
Claims (9)
2. The 2,4,5-trisubstituted pyrimidine hydroxylamine derivative of claim 1, wherein the 2,4,5-trisubstituted pyrimidine hydroxylamine derivative is selected from any of the following compounds:
3- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxypropionamide,
4- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxybutyramide,
5- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxypentanamide,
6- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxyhexanamide,
7- ((5-fluoro-2- ((4-phenoxyphenyl) amino) pyrimidin-4-yl) amino) -N-hydroxyheptanamide.
3. A process for preparing 2,4,5-trisubstituted pyrimidine hydroxylamine derivatives as claimed in claim 1 or 2, wherein compound 1 and amino acid methyl ester are used as starting materials to prepare 2,4,5-trisubstituted pyrimidine hydroxylamine derivatives I by the following reaction scheme:
the preparation method comprises the following steps:
s1, dissolving an initial compound 1 and amino acid methyl ester in isopropanol, adding DIPEA, reacting at 85 ℃ for 4 hours, detecting by TLC (thin layer chromatography), completely reacting, cooling to room temperature, separating out a large amount of solid, filtering, and recrystallizing a filter cake with ethyl acetate to obtain an intermediate 2;
s2, dissolving the intermediate 2 in n-butanol, adding 4-phenoxyaniline, dropwise adding trifluoroacetic acid into the solution, reacting at 110 ℃ for 12h, detecting by TLC (thin layer chromatography), completely reacting, cooling to room temperature, evaporating the solvent under reduced pressure, and carrying out silica gel column chromatography to obtain an intermediate 3;
s3, preparing NH by using potassium hydroxide, hydroxylamine hydrochloride and anhydrous methanol 2 OK solution, dissolving intermediate 3 in NH 2 Reacting in OK solution at room temperature for 2h, detecting by TLC, reacting completely, distilling off solvent under reduced pressure, adding water, adjusting pH to 6-7 with dilute hydrochloric acid, precipitating solid, filtering,recrystallizing the filter cake by methanol or ethyl acetate to obtain 2,4,5-trisubstituted pyrimidine hydroxylamine derivative I.
4. A pharmaceutical composition comprising the 2,4,5-trisubstituted pyrimidine hydroxylamine derivative of claim 1 or 2 or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical formulation comprising an active ingredient comprising the 2,4,5-trisubstituted pyrimidine hydroxyamidoyl derivative of claim 1 or 2 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 4 and a pharmaceutically acceptable adjuvant and/or carrier.
6. An inhibitor, wherein the inhibitor is one of HDAC inhibitor, FLT3 inhibitor and HDAC/FLT3 dual inhibitor, and the active ingredient of the inhibitor is 2,4,5-trisubstituted pyrimidine hydroxylamine derivative or pharmaceutically acceptable salt thereof according to claim 1 or 2.
7. The inhibitor according to claim 6, wherein the inhibitor is a HDAC/FLT3 dual inhibitor, and the active ingredient of the inhibitor is the 2,4,5-tri-substituted pyrimidine hydroxylamine derivative of claim 1 or 2 or a pharmaceutically acceptable salt thereof.
8. The use of a compound which is the 2,4,5-trisubstituted pyrimidine hydroxyamidoyl derivative of claim 1 or 2, or a pharmaceutically acceptable salt thereof, in the preparation of an anti-tumor medicament.
9. The use according to claim 8, wherein the tumor is a lymphoma or leukemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210876172.XA CN115141150B (en) | 2022-07-25 | 2,4, 5-Trisubstituted pyrimidine hydroxylamine acyl derivative and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210876172.XA CN115141150B (en) | 2022-07-25 | 2,4, 5-Trisubstituted pyrimidine hydroxylamine acyl derivative and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115141150A true CN115141150A (en) | 2022-10-04 |
CN115141150B CN115141150B (en) | 2024-04-26 |
Family
ID=
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030134838A1 (en) * | 2001-10-17 | 2003-07-17 | Boehringer Ingelheim Pharma Kg | Trisubstituted pyrimidines |
US20040063705A1 (en) * | 2001-08-22 | 2004-04-01 | Jean-Christophe Harmange | Substituted pyrimidinyl derivatives and methods of use |
US20050113398A1 (en) * | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
CN1910159A (en) * | 2004-01-16 | 2007-02-07 | 诺瓦提斯公司 | 2,4-diaminopyrimidines and their use for inducing cardiomyogenesis |
CN102066340A (en) * | 2008-04-16 | 2011-05-18 | 波托拉医药品公司 | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as SRK or JAK kinases inhibitors |
CN110114344A (en) * | 2016-11-08 | 2019-08-09 | 韩国化学研究院 | New pyrimidine compound and preparation method thereof, and contain pharmaceutical composition of the compound as prevention or treating cancer and the active constituent of diseases associated with inflammation |
CN114181161A (en) * | 2021-12-28 | 2022-03-15 | 南通大学 | (2- ((substituted oxy) phenyl) amino) pyrimidine-4-yl) aminobenzoyl derivative and preparation method and application thereof |
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063705A1 (en) * | 2001-08-22 | 2004-04-01 | Jean-Christophe Harmange | Substituted pyrimidinyl derivatives and methods of use |
US20030134838A1 (en) * | 2001-10-17 | 2003-07-17 | Boehringer Ingelheim Pharma Kg | Trisubstituted pyrimidines |
US20050113398A1 (en) * | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
CN1910159A (en) * | 2004-01-16 | 2007-02-07 | 诺瓦提斯公司 | 2,4-diaminopyrimidines and their use for inducing cardiomyogenesis |
CN102066340A (en) * | 2008-04-16 | 2011-05-18 | 波托拉医药品公司 | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as SRK or JAK kinases inhibitors |
CN110114344A (en) * | 2016-11-08 | 2019-08-09 | 韩国化学研究院 | New pyrimidine compound and preparation method thereof, and contain pharmaceutical composition of the compound as prevention or treating cancer and the active constituent of diseases associated with inflammation |
CN114181161A (en) * | 2021-12-28 | 2022-03-15 | 南通大学 | (2- ((substituted oxy) phenyl) amino) pyrimidine-4-yl) aminobenzoyl derivative and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018233633A1 (en) | Ssao inhibitor | |
CN114230524A (en) | (5-fluoro-2-anilinopyrimidin-4-yl) amino-N-hydroxybenzamide derivative and preparation method and application thereof | |
CA2891851A1 (en) | Heteroaryl alkyne compound and use thereof | |
CN114031559A (en) | Aryl nitrogen-containing heterocycle modified 5-fluoro-pyrimidinediamine benzoate and preparation method and application thereof | |
CN111662296A (en) | Hydroxamic acid derivative containing pyrazolopyrimidine and preparation method and application thereof | |
CA2561281C (en) | Pharmaceutical composition comprising a salt of mirtazapine | |
CN112778318B (en) | Pyrimidopyrazole derivatives for inhibiting xanthine oxidase activity, and preparation method and application thereof | |
CN114181161B (en) | (2- ((substituted oxy) phenyl) amino) pyrimidin-4-yl) aminobenzoyl derivative and preparation method and application thereof | |
CN115141150B (en) | 2,4, 5-Trisubstituted pyrimidine hydroxylamine acyl derivative and preparation method and application thereof | |
CN115141150A (en) | 2,4,5-trisubstituted pyrimidine hydroxylamine acyl derivative and preparation method and application thereof | |
AU2019363595A1 (en) | Co-crystals comprising epicatechin and a carboxy-N-heterocyclic co-crystal former | |
WO2012149093A1 (en) | 2-guanidino-4-oxo-imidazoline derivatives as antimalarial agents, synthesis and methods of use thereof | |
EP0718290B1 (en) | Carboxyalkyl heterocyclic derivatives | |
CN115304550A (en) | Piperazine phenyl amino substituted pyrimidine amino acid derivative, preparation method and application | |
WO2019149089A1 (en) | Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof | |
CN115232076A (en) | Phenylamino substituted pyrimidine amino acid derivative and preparation method and application thereof | |
CN115304551A (en) | 2- ((4-morpholinyl phenyl) amino) pyrimidine amino acid derivative and preparation method and application thereof | |
CN112920167B (en) | Double-target inhibitor targeting FGFR and HDAC, preparation method and application thereof, pharmaceutical composition and medicament | |
CN107849051B (en) | Crystalline forms of substituted aminopyrane derivatives | |
CN114181159B (en) | 2,4, 5-trisubstituted pyrimidine hydrazide derivative and preparation method and application thereof | |
CN114181160A (en) | 2, 4-dianilinopyrimidine-containing hydrazide derivative and preparation method and application thereof | |
WO2024027825A1 (en) | Cdk inhibitor and polymorph of phosphate thereof | |
CN106316982B (en) | Thiazine amide derivative and use thereof | |
WO2010051129A2 (en) | New imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use | |
TW202408510A (en) | Polymorphic forms of CDK inhibitors and phosphates thereof, preparation methods thereof, pharmaceutical compositions containing the same and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |